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Background: Very low quality (VLQ) evidence translates into very low confidence in the balance of risk and
benefits based on the estimates drawn from the body of evidence. Consequently, this assessment highlights gaps
in the research evidence, i.e. knowledge gaps, for important clinical questions. In this way, expert guideline panels
identify priority knowledge gaps that, arguably, should inform the research agenda and prioritize scarce research
economical resources. The extent to which the research agenda reflects the knowledge gaps identified in clinical
practice guidelines is unknown.
Methods: A systematic evaluation of the Endocrine Society (ES) clinical practice guidelines portfolio from 2008 to
2014 was conducted with the objectives to identify (1) recommendations in the ES clinical practice guidelines
based on VLQ evidence reflecting knowledge gaps in endocrinology, and (2) active research designed to address
these gaps by searching the clinical trial registry, clinicaltrials.gov, using terms describing patients (diseases),
interventions, comparison, and outcomes.
Results: In 25 ES guidelines, we found 660 recommendations, of which 131 (20 %) were supported by VLQ evidence.
Clinical trialists are attempting to answer 28 (21 %) of these knowledge gaps by performing 69 clinical trials.
Conclusion: The research enterprise is addressing one in five knowledge gaps identified in clinical practice
recommendations in endocrinology. These findings suggest an inefficiency in the allocation of very scarce research
economical resources. Linking the research agenda to evidence gaps in clinical practice guidelines may improve both
the efficiency of the research enterprise and the translation of evidence into more confident clinical practice.
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The Endocrine Society (ES) has created clinical practice
guidelines to aid clinicians in the care of patients with
endocrine disorders. In 2005, the ES adopted the Grading
of Recommendations, Assessment, Development and
Evaluation (GRADE) Group system [1–4]. The GRADE
approach rates the panel’s confidence in the risk estimates
of favorable and unfavorable outcomes. This confidence in
the estimates is captured by classifying the quality of the
body of evidence supporting a recommendation into one* Correspondence: montori.victor@mayo.edu
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ity (VLQ) [1–4]. VLQ evidence results when the body of
evidence is comprised of studies at high risk of bias, yield-
ing imprecise results or results of indirect relevance to the
recommendation, and/or results that are inconsistent
across studies or are not fully reported. VLQ evidence
translates into very low confidence in the balance of risk
and benefits based on the estimates drawn from the body
of evidence [3, 4]. Consequently, this assessment high-
lights gaps in the research evidence, i.e. knowledge gaps,
for important clinical questions. Since these knowledge
gaps affect the assessments about the balance of benefits
and harms of alternative courses of action they reduce our
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VLQ evidence.
A recent study showed that low to very low quality
evidence, largely derived from small observational stud-
ies, supported most endocrinology guideline recommen-
dations [5, 6]. To this extent, guidelines that explicitly
account for confidence in estimates from the body of
evidence, such as ES guidelines, can be used to identify
important knowledge gaps and guide the research agenda.
This is particularly important in the face of scarce, re-
search dollars. Moreover, it has been previously estimated
that 85 % of research is of low impact or wasted mainly
due to being unnecessary, poorly designed, biased, un-
usable, incompletely published, or simply addressing the
wrong research question. A better connection between
knowledge gaps identified in practice guidelines and the
research enterprise could reduce research waste [7–12].
To explore the integrity of the pipeline connecting know-
ledge gaps with ongoing research, we conducted a study
using ES guidelines.
Methods
We conducted a systematic evaluation of the available
ES clinical practice guidelines to identify clinical recom-
mendations that are based on VLQ evidence and that
potentially reflect knowledge gaps in endocrinology.
Using the ES guideline web site, we identified and re-
trieved all ES clinical practice guidelines issued from
2008 to 2014 [13–38]. For each guideline, two reviewers
working independently searched and extracted the num-
ber of graded recommendations in each guideline and
those rated as based on VLQ evidence. Guideline panels
following the GRADE approach, as is the case with ES
guidelines, rate evidence as VLQ when the body of evi-
dence produces estimates about which we have very low
confidence. Studies produce low-confidence estimates
when they are at high risk of bias, produce results that
are of indirect relevance to the recommendation, impre-
cise or inconsistent, or when there is evidence of incom-
plete and biased reporting [3, 4, 39].
Because of problems with classification, some recom-
mendations based on VLQ evidence should not have
been graded as they represent best practice statements
in which there is no sensible alternative. In this sense,
best practice recommendations are thought to do sub-
stantially more good than harm (or vice versa) and
therefore no one would consider doing a study to defini-
tively establish the answer to the implicit question [40].
Examples of best practice recommendations include:
(1) “We suggest that female-to-male transsexual persons
evaluate the risks and benefits of including total hysterec-
tomy and oophorectomy as part of sex reassignment
surgery”, and (2) “In patients presenting with heart fail-
ure, initial assessment should be made of the patient’sability to perform routine/desired activities of daily
living” [20, 38, 41]. After excluding these, the crude
inter-observer agreement for the identification of recom-
mendations based of VLQ evidence was 96 %.
We then identified the research questions relevant to
these knowledge gaps in terms of patients, interventions,
comparisons, and outcomes (PICO). For each VLQ
evidence item, we drafted a research question that a
clinical trial could answer using the PICO format
(e.g. Patients – patients with large adrenal pheochromocy-
tomas; Intervention – minimally invasive adrenalec-
tomy; Comparison – open resection adrenalectomy;
Outcome – complete tumor resection, tumor rupture
avoidance, and local recurrence rates) [1, 35, 39]. The
objective of this step was to make the underlying
questions explicit thus ensuring reproducibility of our
methods. To calibrate this process, two researchers in-
dependently produced these questions for 11 recom-
mendations with an initial agreement of 80 %. This
process was repeated until the agreement was 100 %,
achieved after 20 recommendations.
We then searched the clinicaltrials.gov database for ac-
tive studies (randomized and observational) addressing
the questions identified from the guidelines. Since 2000,
this registry has emerged as the most complete including
trials from 188 countries. A clinical trial was deemed eli-
gible if it addressed the PICO question with at least one
of the necessary outcomes. For each eligible clinical trial,
we extracted the study design, source of funding, year of
entry, and the sample size. Although we did not look for
publication of results, we excluded trials completed 5 or
more years prior to the date of guideline publication. Re-
viewers working independently searched the clinical trial
registry until 100 % agreement, a point reached after
searching for 20 questions. A single reviewer completed
the search for the rest of the questions.
Statistical analysis
We performed a descriptive analysis and summarized
continuous variables as mean (SD) and presented per-
centages in cases of categorical variables.
Results
We identified 25 Clinical Practice Guidelines from the
ES with 660 recommendations, of which 209 (32 %)
were supported by VLQ evidence [8–32]. After exclud-
ing 78 (12 %) best practice statements, the total was 131
(20 %) recommendations based on VLQ evidence (Fig. 1).
The majority of the guidelines supported the care of pa-
tients with pituitary, gonadal, and adrenal disorders [13],
and most recommendations supported by VLQ evidence
came from these guidelines (24 %; Fig. 2).
Active research was identified for 28 (21 %) of these
131 recommendations represented by 69 clinical studies
Fig. 1 Selection process. ES, Endocrine Society; VLQ, Very low quality
Fig. 2 Proportion of recommendations based on VLQ evidence with and without active research studies. VLQ, Very low quality; Rec., Recommendation;
AR., Active research; PAG, Pituitary adrenal and gonad axis; CVD, Cardiovascular disease. Numbers in percentage correspond to recommendations based
on VLQ evidence with active research
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taking into consideration those with active research;
Fig. 1). Of these, 35 (51 %) were randomized trials and
34 (49 %) were observational. Thirteen reported industry
funding and six were multicenter studies. Of the 69
active studies, 42 (60 %) were in the guidelines of thyroid
dysfunction during pregnancy, testosterone therapy in
adult men, and diagnosis of Cushing syndrome which
had a total of 32 recommendations supported by VLQ
evidence, of which 15 had at least one active research
study.
Most of the identified clinical trials addressed know-
ledge gaps affecting recommendations for patients with
thyroid disorders (70 %); the least dealt with were gaps
in the evidence for care of patients with diabetes, obesity,
and cardiovascular disease (16 %; Fig. 2).
Discussion
Important knowledge gaps are evident in 10 of every
50 ES clinical practice guideline recommendations, of
which the research enterprise is actively addressing, at
best, two. Moreover, of the active trials, 60 % are trying
to improve the quality of evidence in only three of the
25 guidelines. In some cases, several studies are actively
addressing the same question. The research enterprise,
thus characterized, poorly reflects the knowledge gaps at
the frontline of endocrine practice, covering these gaps
incompletely and sometimes redundantly. Multiple ex-
planations exist for these observations. The research
enterprise may not be aware of these gaps because
funding agencies and researchers do not use clinical
practice guidelines to identify knowledge gaps, or they
may be responding to these gaps with basic studies
that are not in the registry. Alternatively, ES expert
ratings of confidence in estimates evidence have not
been explicitly communicated to researchers and funders
to facilitate the development of a practice-relevant
research agenda.
This cross-sectional study contributes to the under-
standing of a seemingly broken research pipeline. How-
ever, there are dynamic aspects that only a longitudinal
study could answer. For example, in its 2014 version, the
ES guideline on Androgen Therapy in Women had seven
recommendations based on VLQ evidence, all new since
its 2006 version [42]. Conversely, the evidence supporting
two of their 2006 recommendations was upgraded in 2014
from warranting very low to warranting low confidence in
the estimates [38, 42]. How these changes result from the
manner in which the research enterprise responds to
knowledge gaps merits further study.
To our knowledge, there is no comprehensive reposi-
tory of knowledge gaps in endocrinology. This study par-
tially reflects the coverage of the current ES guideline
portfolio based on our selection of recommendationssupported by VLQ evidence, instead of the much larger
set of recommendations based on low quality evidence.
A key advantage of the portfolio that enabled this study
is the ES’s early adoption of GRADE, which enables the
separation of the rating of evidence (used here) from the
grading of the strength of recommendation [4]. Further,
we used the clinicaltrials.gov registry which, despite be-
ing the largest, may have missed research (e.g. well-
designed observational studies, not registered studies),
particularly outside the United States. Additionally, stud-
ies published after the publication of the clinical guide-
lines that could have assessed these gaps were not part
of our analysis. Nevertheless, we identified knowledge
gaps in the ES clinical practice guidelines in duplicate
and performed a search of clinical trials to address them
after high reproducibility was achieved between each of
the independent reviewers.
We are also aware that, even though panels may be
the best way to identify research gaps, it could be easily
argued that this does not automatically mean that trials
should be conducted in those areas, e.g. the needed
studies might be prohibitively expensive, research gaps
might be difficult to study, or the science field is not de-
veloped enough to support the conduct of clinical trials.
On the other hand, panels choose areas of clinical rele-
vance to formulate recommendations. Often, these repre-
sent ongoing practice, which is unlikely to be supported
solely by mechanistic hypotheses or basic science data.
While we do not know the extent to which our findings
apply to other areas of medicine, they may very well
represent a trigger to examine the research pipeline
and improve the quality and relevance of the evidence.
A functional pipeline connecting evidence to recom-
mendations and back can ultimately better support de-
cision making by patients, clinicians, policy makers,
and funding agencies.Conclusion
Researchers are addressing only one in five knowledge
gaps identified in clinical practice recommendations in
endocrinology. Linking the research agenda to evidence
gaps in guidelines may improve both the efficiency of
the research enterprise and the translation of evidence
into practice by increasing the value and reducing the
waste in research.Abbreviations
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